How to Choose a Peptide Purity Target for Research Procurement

01

Start with the intended research workflow

A useful purity target begins with the downstream research workflow, not with the largest percentage available in a dropdown. A screening reagent, an analytical reference project and a conjugation intermediate may require different controls.

Describe what happens after receipt: whether the peptide will be screened, quantified, conjugated, used in a binding workflow or subjected to additional purification. The manufacturer can then evaluate whether the requested target is technically meaningful and commercially proportionate.

• Research stage and intended workflow
• Sensitivity to closely related impurities
• Need for downstream conjugation or labeling
• Required amount after purification
• Analytical records needed with the batch

02

Do not use purity as a substitute for identity or content

HPLC area percentage describes the chromatographic result under a stated method. It does not, by itself, prove that the main peak is the intended sequence or that a vial contains a specified net amount.

A complete RFQ should therefore separate target purity, identity evidence and amount or content requirements. Where applicable, mass-spectrometric evidence may support molecular identity, while other agreed methods or process controls address additional attributes.

03

Account for sequence-dependent difficulty

Two peptides of equal length can behave very differently. Hydrophobic regions, charged clusters, aggregation, difficult couplings and closely related deletion sequences can affect synthesis and purification.

A manufacturer should review the actual sequence and modification pattern before confirming an aggressive purity target. Feasibility review is especially important when the buyer also requires large scale, short lead time or multiple modifications.

04

Understand the purification and yield tradeoff

Preparative purification separates the desired component from impurities, but tighter collection criteria can reduce recovered yield. A higher target may therefore require more crude material, additional purification work or a revised delivery quantity.

The quotation should distinguish the requested final quantity from the synthesis scale. If yield risk is material, the manufacturer should state whether the quote guarantees a final delivered amount, provides a range or requires a feasibility stage.

05

Define the analytical method context

A purity value is interpretable only with method context. Column chemistry, mobile phase, gradient, detector wavelength, sample preparation and integration approach can change the observed chromatogram.

For custom work, request the agreed analytical output and enough method information to interpret it. Method suitability should be proportionate to the decision the result will support; ICH Q2(R2) provides a formal framework for analytical procedure validation within its stated regulatory scope, but it is not a blanket certification for every research peptide.

06

Write an acceptance criterion before production

The target should be expressed as an agreed acceptance criterion rather than a promotional phrase. Define whether the result is a minimum threshold, what method applies and what happens if the batch does not meet it.

Do not retroactively change the criterion after seeing a chromatogram. If a project is exploratory and feasibility is uncertain, document that status and agree how the next decision will be made.

• Target purity and applicable analytical method
• Identity evidence required
• Final delivered amount and format
• Required chromatogram, spectrum or COA fields
• Decision path for an out-of-criterion result

07

Use the RFQ to balance purity, scale and timeline

A well-structured RFQ allows the manufacturer to propose a practical configuration instead of simply accepting an unrealistic number. Include the full sequence, modification and terminal requirements, target purity, final amount, packaging, destination and desired timing.

Stablize Peptides can review custom peptide synthesis requirements and provide a feasibility-based quotation. Detailed capability, sequence and method information is shared during the inquiry rather than presented as a universal public promise.

RELATED GUIDANCE

Continue the procurement review